Patents by Inventor Peter A. Sieling
Peter A. Sieling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240075129Abstract: Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Also disclosed are compositions for assaying the presence of anti-viral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.Type: ApplicationFiled: October 17, 2023Publication date: March 7, 2024Applicant: ImmunityBio, Inc.Inventors: Patrick Soon-Shiong, Peter Sieling, Kayvan Niazi, Shahrooz Rabizadeh, Lise Geissert, Annie Shin, Adrian Rice, Elizabeth Gabitzsch, Jeffrey Safrit, Leonard Sender
-
Publication number: 20240027462Abstract: The invention relates to array-based methods for identification of neoepitope reactive T cells and to compositions produced using such methods. Aspects of the invention relate to rapid and reliable methods to identify neoepitope reactive T cells.Type: ApplicationFiled: October 8, 2021Publication date: January 25, 2024Inventors: Peter SIELING, Kayvan NIAZI, Clifford Anders OLSON, Adam D. LAZAR
-
Patent number: 11857620Abstract: Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Also disclosed are compositions for assaying the presence of antiviral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.Type: GrantFiled: March 10, 2021Date of Patent: January 2, 2024Assignee: ImmunityBio, Inc.Inventors: Patrick Soon-Shiong, Peter Sieling, Kayvan Niazi, Shahrooz Rabizadeh, Lise Geissert, Annie Shin, Adrian Rice, Elizabeth Gabitzsch, Jeffrey Safrit, Leonard Sender
-
Publication number: 20230338508Abstract: Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Also disclosed are compositions for assaying the presence of antiviral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.Type: ApplicationFiled: March 10, 2021Publication date: October 26, 2023Inventors: Patrick Soon-Shiong, Peter Sieling, Kayvan Niazi, Shahrooz Rabizadeh, Lise Geissert, Annie Shin, Adrian Rice, Elizabeth Gabitzsch, Jeffrey Safrit, Leonard Sender
-
Publication number: 20230236172Abstract: Compositions and methods are presented that allow for detection and prediction of an immune response in a subject that is selected to receive or that has received a vaccine. In selected embodiments, whole blood is used as starting material to obtain both dendritic cells and T cells, and synthetic or recombinant polypeptide(s) are used that include an antigen of the vaccine. The dendritic cells are then exposed to the synthetic or recombinant polypeptide(s), and thusly exposed dendritic cells are combined with the T cells to generate antigen reactive T cells. For detection or quantification, the antigen reactive T cells are expanded in vitro prior to ELISPOT or FACS analysis. Advantageously, such systems and methods are especially suitable for ascertaining an immune response against cancer antigens following vaccination with an anti-cancer vaccine.Type: ApplicationFiled: March 4, 2021Publication date: July 27, 2023Applicant: NantCell, Inc.Inventor: Peter Sieling
-
Publication number: 20230086390Abstract: Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Also disclosed are compositions for assaying the presence of antiviral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.Type: ApplicationFiled: March 10, 2021Publication date: March 23, 2023Inventors: Patrick Soon-Shiong, Peter Sieling, Kayvan Niazi, Shahrooz Rabizadeh, Lise Geissert, Annie Shin, Adrian Rice, Elizabeth Gabitzsch, Jeffrey Safrit, Leonard Sender
-
Publication number: 20220370587Abstract: Two-component vaccine formulations and methods are contemplated where the vaccine has an adjuvant component and a therapeutic component. The therapeutic component comprises preferably a recombinant therapeutic virus encoding a therapeutic antigen while the adjuvant component comprises a non-host cell or immune stimulating portion thereof. Notably, use of the adjuvant component will result in significant uptake of the therapeutic component into immune competent cells, even in the absence of receptors for entry of the therapeutic component. In addition, such adjuvant also stimulates expression of the therapeutic antigen.Type: ApplicationFiled: March 1, 2022Publication date: November 24, 2022Inventors: Kayvan Niazi, Raymond Wong, Peter Sieling, Philip T. Liu
-
Publication number: 20220347213Abstract: T cells are transfected with a recombinant RNA molecule that encodes at least one of an alpha chain and a beta chain of a CD1b restricted T cell receptor. Preferably, the so prepared T cells are used as a cell-based therapeutic composition to treat tuberculosis.Type: ApplicationFiled: August 6, 2019Publication date: November 3, 2022Inventors: Wade Richardson, Ting Wu, Peter Sieling, Kayvan Niazi
-
Publication number: 20220170099Abstract: Single cell analysis from tumor tissue comprising tumor cells and immune competent cells and from peripheral white blood cells are used to obtain an immunome signature, and to gain information about the TCR repertoire. Such information is then employed to generate recombinant and patient specific therapeutic cells, including T cells (including T effector memory, T memory stem, naïve T, T central memory, CD8+ T, and CD4+ T cells), NK cells (cord-blood derived or PBMC derived or NK92), NKT cells, and dendritic cells.Type: ApplicationFiled: July 24, 2020Publication date: June 2, 2022Inventors: Shahrooz Rabizadeh, Patrick Soon-Shiong, Peter Sieling, Stephen Charles Benz, Andrew Nguyen
-
Patent number: 11298414Abstract: Two-component vaccine formulations and methods are contemplated where the vaccine has an adjuvant component and a therapeutic component. The therapeutic component comprises preferably a recombinant therapeutic virus encoding a therapeutic antigen while the adjuvant component comprises a non-host cell or immune stimulating portion thereof. Notably, use of the adjuvant component will result in significant uptake of the therapeutic component into immune competent cells, even in the absence of receptors for entry of the therapeutic component. In addition, such adjuvant also stimulates expression of the therapeutic antigen.Type: GrantFiled: August 9, 2019Date of Patent: April 12, 2022Assignee: NantBio, Inc.Inventors: Kayvan Niazi, Raymond Wong, Peter Sieling, Philip T. Liu
-
Publication number: 20210093669Abstract: Provided herein are methods of in-vitro primary T cell growth that enrich T cells in a blood sample, stimulate the T cells with anti-CD2, anti-CD3, and/or anti-CD28 and that expand the T cells with a cytokine. Also provided are methods of treating a tumor in a patient using the expanded T cells.Type: ApplicationFiled: September 25, 2020Publication date: April 1, 2021Inventors: Krsto Sbutega, Peter Sieling, Adam D. Lazar, Kayvan Niazi
-
Publication number: 20200282037Abstract: A pharmaceutical compositions and methods for immunotherapy are provided. The pharmaceutical composition includes a genetically-engineered bacterium expressing a human disease-related antigen(s), preferably two or more patient-specific tumor antigens as a polytope. The bacterium has genetically engineered lipopolysaccharide or a patient's own endosymbiotic bacterium so that the bacterium expresses endotoxin at a low level, which is insufficient to induce a CD-14 mediated sepsis. The genetically-engineered bacterium can be administered to the patient, either systemically or locally, to induce tumor-specific immune response.Type: ApplicationFiled: June 15, 2018Publication date: September 10, 2020Inventors: Kayvan NIAZI, Adam LAZAR, Philip T. LIU, Annie SHIN, Peter SIELING
-
Publication number: 20200101149Abstract: Two-component vaccine formulations and methods are contemplated where the vaccine has an adjuvant component and a therapeutic component. The therapeutic component comprises preferably a recombinant therapeutic virus encoding a therapeutic antigen while the adjuvant component comprises a non-host cell or immune stimulating portion thereof. Notably, use of the adjuvant component will result in significant uptake of the therapeutic component into immune competent cells, even in the absence of receptors for entry of the therapeutic component. In addition, such adjuvant also stimulates expression of the therapeutic antigen.Type: ApplicationFiled: August 9, 2019Publication date: April 2, 2020Inventors: Kayvan NIAZI, Raymond WONG, Peter SIELING, Philip T. LIU
-
Patent number: 10252269Abstract: Methods and devices are provided for focusing and/or sorting activated T cells. The device comprises a microfluidic channel comprising a plurality of electrodes arranged to provide dielectrophoretic (DEP) forces that are perpendicular to forces from hydrodynamic flows along the channel. The device may be configured to apply voltages to a plurality of electrodes in a first upper region of the microfluidic channel to focus the cells into a single flow, and to apply different voltages to a plurality of electrodes in a second downstream region of the microfluidic channel to sort cells based on size. The output of the microfluidic channel may diverge into multiple channels, wherein cells of various sorted sizes are directed into the appropriate output channel.Type: GrantFiled: November 17, 2017Date of Patent: April 9, 2019Assignees: NANTBIO, INC., NANOCAV, LLCInventors: Yu-Chun Kung, Ting-Hsiang Wu, Peter Sieling, Kayvan Niazi
-
Publication number: 20180141048Abstract: Methods and devices are provided for focusing and/or sorting activated T cells. The device comprises a microfluidic channel comprising a plurality of electrodes arranged to provide dielectrophoretic (DEP) forces that are perpendicular to forces from hydrodynamic flows along the channel. The device may be configured to apply voltages to a plurality of electrodes in a first upper region of the microfluidic channel to focus the cells into a single flow, and to apply different voltages to a plurality of electrodes in a second downstream region of the microfluidic channel to sort cells based on size. The output of the microfluidic channel may diverge into multiple channels, wherein cells of various sorted sizes are directed into the appropriate output channel.Type: ApplicationFiled: November 17, 2017Publication date: May 24, 2018Inventors: Yu-Chun KUNG, Ting-Hsiang WU, Peter SIELING, Kayvan NIAZI
-
Patent number: 5853737Abstract: The present invention is based on the observation that CD1 functions to present foreign and autoimmune antigens to a select subpopulation of T-cells. Based on this observation, the present invention provides methods for detecting the presence of a CD1-presented antigen in a sample, methods for purifying CD1-presented antigens, vaccines containing CD1-presented antigens, methods of blocking CD1 antigen presentation, methods of identifying and/or isolating CD1 blocking agents, methods of inducing CD1 expression, and T-cell lines for use in the methods disclosed herein. The CD1-presented antigens of the invention, unlike MHC-presented antigens, are non-polypeptide hydrophobic antigens. In particular, a CD1-presented antigen isolated from several mycobacterial species is a lipoarabinomannan (LAM).Type: GrantFiled: October 13, 1994Date of Patent: December 29, 1998Assignees: Brigham and Women's Hospital, University of California, Los Angeles, Colorado State University Research FoundationInventors: Robert L. Modlin, Peter A. Sieling, Michael B. Brenner, Steven A. Porcelli, Patrick J. Brennan